{
    "nct_id": "NCT06847269",
    "official_title": "CAR T CELL Therapy for Pediatric, Adolescent and Young Adult Patients With CD19-Positive Leukemia: An Investigation of Lymphodepleting Chemotherapy Pharmacokinetics",
    "inclusion_criteria": "* CD19+ leukemia** with any of the following:\n\n  * Refractory disease (primary or in relapse)\n  * 2nd or greater relapse\n  * Any relapse after allogeneic hematopoietic cell transplantation\n  * 1st relapse if patient requires an allogeneic HCT as part of standard of care relapse therapy, but is found to be ineligible and/or unsuitable for HCT\n\n    * must be confirmed to be CD19+ within 3 months prior to enrollment for treatment\n* Age: ≤ 21 years of age\n* Karnofsky or Lansky (age-dependent) performance score ≥ 50 (Appendix A)\n* Estimated life expectancy of > 12 weeks. Patients with a history of prior allogeneic hematopoietic cell transplantation [HCT] must be clinically recovered from prior HCT therapy, have no evidence of active GVHD and have not received a donor lymphocyte infusion (DLI) within the 28 days prior to apheresis\n* For females of child bearing age:\n\n  * Not lactating with intent to breastfeed\n  * Not pregnant with negative serum pregnancy test within 7 days prior to enrollment\nHealthy volunteers allowed\nMust have maximum age of 21 Years",
    "exclusion_criteria": "* Known primary immunodeficiency\n* History of HIV infection\n* Severe intercurrent bacterial, viral or fungal infection\n* History of hypersensitivity reactions to murine protein-containing products\n* Known contraindication to receiving protocol defined lymphodepleting chemotherapy regimen\n\nTreatment\n\nInclusion Criteria:\n\n* Age: ≤ 21 years of age\n* Estimated life expectancy of > 8 weeks\n* Detectable disease\n* Prior to planned CAR T cell infusion, patients with a history of prior allogeneic HCT must:\n\n  * be at least 3 months from HCT\n  * have no evidence of active GVHD\n  * have not received a donor lymphocyte infusion (DLI) within the 28 days prior to planned infusion\n* Adequate cardiac function defined as left ventricular ejection fraction > 40%, or shortening fraction ≥ 25%\n* EKG without evidence of clinically significant arrhythmia\n* Adequate renal function defined as creatinine clearance or radioisotope GFR ³ 50 ml/min/1.73m2 (GFR ³ 40 ml/min/1.73m2 if < 2 years of age)\n* Adequate pulmonary function defined as forced vital capacity (FVC) ≥ 50% of predicted value; or pulse oximetry ≥ 92% on room air if patient is unable to perform pulmonary function testing\n* Karnofsky or Lansky (age-dependent) performance score ≥ 50 (Appendix A)\n* Total Bilirubin ≤ 3 times the upper limit of normal for age, except in subjects with Gilbert's syndrome\n* Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) ≤ 5 times the upper limit of normal for age\n* Has recovered from all NCI CTAE grade III-IV, non-hematologic acute toxicities from prior therapy\n* For patients of child bearing age:\n\n  * Not lactating with intent to breastfeed\n  * Not pregnant with negative serum pregnancy test within 7 days prior to enrollment\n  * If sexually active, agreement to use birth control until 6 months after T cell infusion.\n\nExclusion Criteria:\n\n* Active CNS-3 disease\n* Known primary immunodeficiency\n* History of HIV infection\n* Evidence of active, uncontrolled neurologic disease\n* Severe, uncontrolled bacterial, viral or fungal infection\n* History of hypersensitivity reactions to murine protein-containing products\n* Known contraindication to receiving protocol defined lymphodepleting chemotherapy regimen",
    "miscellaneous_criteria": "Autologous Apheresis and Manufacturing"
}